Achieve Life Sciences (NASDAQ:ACHV) Releases Earnings Results, Misses Expectations By $0.03 EPS

Achieve Life Sciences (NASDAQ:ACHV) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.22) by ($0.03), Yahoo Finance reports. During the same quarter last year, the business posted ($0.43) EPS.

Achieve Life Sciences Stock Up 0.9 %

Shares of NASDAQ:ACHV traded up $0.04 during midday trading on Wednesday, hitting $4.40. The stock had a trading volume of 18,914 shares, compared to its average volume of 154,900. The company’s 50-day moving average price is $4.80 and its 200-day moving average price is $4.68. Achieve Life Sciences has a fifty-two week low of $3.03 and a fifty-two week high of $5.98. The company has a market capitalization of $151.10 million, a P/E ratio of -3.38 and a beta of 1.54.

Analyst Ratings Changes

Several research analysts have recently commented on ACHV shares. Oppenheimer lowered their target price on shares of Achieve Life Sciences from $18.00 to $11.00 and set an “outperform” rating on the stock in a report on Monday, May 13th. Jonestrading started coverage on Achieve Life Sciences in a research note on Wednesday, April 17th. They set a “buy” rating and a $20.00 price objective on the stock.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.